Clinical Trial Update: A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis [Phase 2, Phase 3]

View source ↗

Summary

This update reports a pediatric Phase 2/3 study of tildrakizumab for chronic plaque psoriasis, which is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Ilumya (tildrakizumab)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Moderate-to-severe Chronic Plaque Psoriasis | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING